Discover
LGND
Ligand Pharmaceuticals Incorporated
305.47
1 x 303.00
1 x 486.35
bid
ask
+
11.48
3.90%
5 @ 08:05 AM
305.24 -0.23 (0.08%)
| Ytd | 61.56% | |
| 1y | 130.61% |
295.35
day range
305.47
129.55
52 week range
326.63
| Open | 296.97 | Prev Close | 293.99 | Low | 295.35 | High | 305.47 | Mkt Cap | 6.12B |
| Vol | 162.77K | Avg Vol | 341.64K | EPS | 8.34 | P/E | 36.63 | Forward P/E | 34.01 |
| Beta | 1.10 | Short Ratio | 4.25 | Inst. Own | 107.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 07-02 | Earning | 08-06 | 50-d Avg | 263.66 | 200-d Avg | 215.63 | 1yr Est | 311.30 |
| Income Statement | |||
| Total Revenue | 51.72M | ||
| Revenues (USD) | 51.72M | ||
| Cost of Revenue | 3.27M | ||
| Gross Profit | 48.45M | ||
| Operating Expenses | 31.08M | ||
| Research and Development Expense | 2.15M | ||
| Selling, General and Administrative Expense | 20.84M | ||
| Operating Income | 17.37M | ||
| Interest Expense | 1.75M | ||
| Income Tax Expense | -10.91M | ||
| Net Income | -13.34M | ||
| Net Income Common Stock | -13.34M | ||
| Net Income Common Stock (USD) | -13.34M | ||
| Consolidated Income | -13.34M | ||
| Earnings per Basic Share | -0.67 | ||
| Earnings per Basic Share (USD) | -0.67 | ||
| Earnings per Diluted Share | -0.67 | ||
| Earning Before Interest & Taxes (EBIT) | -22.51M | ||
| Earning Before Interest & Taxes (USD) | -22.51M | ||
| Weighted Average Shares | 19.88M | ||
| Weighted Average Shares Diluted | 19.88M | ||
| Balance Sheet | |||
| Cash and Equivalents | 115.08M | ||
| Cash and Equivalents (USD) | 115.08M | ||
| Investments | 783.61M | ||
| Investments Current | 664.33M | ||
| Investments Non-Current | 119.29M | ||
| Trade and Non-Trade Receivables | 53.38M | ||
| Current Assets | 865.42M | ||
| Total Assets | 1.53B | ||
| Debt Current | 1.09M | ||
| Total Debt | 451.98M | ||
| Current Liabilities | 40.67M | ||
| Debt Non-Current | 450.89M | ||
| Total Liabilities | 534.78M | ||
| Accumulated Retained Earnings (Deficit) | 594.74M | ||
| Accumulated Other Comprehensive Income | 5.39M | ||
| Shareholders Equity | 997.32M | ||
| Shareholders Equity (USD) | 997.32M | ||
| Assets Non-Current | 666.69M | ||
| Total Debt (USD) | 451.98M | ||
| Goodwill and Intangible Assets | 318.88M | ||
| Inventory | 13.27M | ||
| Liabilities Non-Current | 494.12M | ||
| Trade and Non-Trade Payables | 5.26M | ||
| Tax Assets | 9.89M | ||
| Tax Liabilities | 24.51M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 8.70M | ||
| Net Cash Flow from Financing | -14.13M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -59.83M | ||
| Capital Expenditure | -228.00K | ||
| Issuance (Purchase) of Equity Shares | 7.65M | ||
| Issuance (Repayment) of Debt Securities | -57.00K | ||
| Net Cash Flow from Investing | -94.35M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -94.12M | ||
| Net Cash Flow from Operations | 48.69M | ||
| Effect of Exchange Rate Changes on Cash | -44.00K | ||
| Share Based Compensation | -11.13M | ||